Latest news with #Danaher
Yahoo
4 hours ago
- Business
- Yahoo
3 Large-Cap Stocks We Think Twice About
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players. These trade-offs can cause headaches for even the most seasoned professionals, which is why we started StockStory - to help you find high-quality companies that can grow their earnings no matter what. Keeping that in mind, here are three large-cap stocks that may face near-term headwinds and some other investments you should consider instead. Microchip Technology (MCHP) Market Cap: $38.06 billion Spun out from General Instrument in 1987, Microchip Technology (NASDAQ: MCHP) is a leading provider of microcontrollers and integrated circuits used mainly in the automotive world, especially in electric vehicles and their charging devices. Why Do We Think MCHP Will Underperform? Annual sales declines of 3.6% for the past five years show its products and services struggled to connect with the market during this cycle Operating margin declined by 11.6 percentage points over the last five years as its sales cratered Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 16 percentage points Microchip Technology is trading at $70.53 per share, or 62.5x forward P/E. Dive into our free research report to see why there are better opportunities than MCHP. Danaher (DHR) Market Cap: $145.3 billion Born from a real estate investment trust that transformed into a manufacturing powerhouse, Danaher (NYSE:DHR) is a global science and technology company that provides specialized equipment, software, and services for biotechnology, life sciences, and diagnostics. Why Does DHR Fall Short? Products and services are facing significant end-market challenges during this cycle as sales have declined by 2.9% annually over the last two years Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth 7.9 percentage point decline in its free cash flow margin over the last five years reflects the company's increased investments to defend its market position At $203 per share, Danaher trades at 25.1x forward P/E. Check out our free in-depth research report to learn more about why DHR doesn't pass our bar. Regeneron (REGN) Market Cap: $59.03 billion Founded by scientists who wanted to build a company where science could thrive, Regeneron Pharmaceuticals (NASDAQ:REGN) develops and commercializes medicines for serious diseases, with key products treating eye conditions, allergic diseases, cancer, and other disorders. Why Does REGN Give Us Pause? Scale is a double-edged sword because it limits the company's growth potential compared to its smaller competitors, as reflected in its below-average annual revenue increases of 6.7% for the last two years Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 12.3 percentage points Waning returns on capital imply its previous profit engines are losing steam Regeneron's stock price of $558.67 implies a valuation ratio of 14x forward P/E. To fully understand why you should be careful with REGN, check out our full research report (it's free). High-Quality Stocks for All Market Conditions When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that's already erased most losses. Don't let fear keep you from great opportunities and take a look at Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
5 hours ago
- Business
- Yahoo
Aldevron Launches New Innovation Center in Waltham, MA
Strategic expansion places Aldevron at the heart of the Boston biotech corridor, fueling next-generation breakthroughs in genomic medicine FARGO, N.D. & WALTHAM, Mass., July 30, 2025--(BUSINESS WIRE)--Aldevron, a Danaher company, and a global leader in the production of DNA, RNA and protein in the genomic medicine space, today announced the planned opening of its new Innovation Center in Waltham, Massachusetts. The milestone marks a bold step in Aldevron's mission to accelerate innovation in genomic medicines while deepening its presence in one of the world's most dynamic biotech hubs. The new Waltham site is designed to fast-track advancements in the manufacture of DNA, RNA and proteins for advanced therapies, expanding Aldevron's capabilities in cell-free DNA, molecular biology, gene editing, and mRNA analytics. By establishing a base in the Boston area, Aldevron is positioning itself at the epicenter of biotech innovation—enabling closer collaboration with clients, faster project timelines and enhanced support for the development of advanced therapies. "Establishing a presence in Waltham puts Aldevron at the crossroads of scientific discovery," said Venkata Indurthi, Chief Scientific Officer at Aldevron. "This Innovation Center is a launchpad for transformative research, empowering us to innovate, collaborate and grow alongside the brightest minds in biotech." The Waltham Innovation Center will complement Aldevron's established scientific teams in Fargo, ND, and Madison, WI, and will serve as a catalyst for recruiting top talent from Boston's vibrant biotech community. "Our recent role in the groundbreaking 'Baby KJ' CRISPR therapy delivery demonstrates the life-changing impact that comes from investing in innovation," said Jennifer Meade, President of Aldevron. "As one of the most established biotech partners in the U.S., this expansion is a natural evolution—opening new opportunities for growth, deeper client partnerships and greater support for the scientists shaping the future of medicine." About Aldevron Founded in 1998, Aldevron is a global leader in enabling the development of next-generation genomic medicines. As part of Danaher Corporation, Aldevron empowers scientists and innovators worldwide to advance transformative therapies that are redefining the future of medicine. Aldevron's expertise and integrated solutions have supported landmark achievements—including playing a key role in manufacturing the world's first mRNA-based personalized CRISPR therapy. With facilities in Fargo, ND, Madison, WI and Waltham, MA, Aldevron is at the forefront of accelerating scientific discovery and expanding the possibilities of gene editing, gene therapy and other breakthrough modalities. By partnering with leading researchers and organizations, Aldevron is helping to turn the promise of genomic medicine into reality for patients around the globe. To learn more about how Aldevron is advancing biological science, visit and follow the company on LinkedIn, Facebook and YouTube. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at View source version on Contacts Media Contact: Ellen ShaferSenior Director of (701) 219-0333
Business Wire
5 hours ago
- Business
- Business Wire
Aldevron Launches New Innovation Center in Waltham, MA
BUSINESS WIRE)--Aldevron, a Danaher company, and a global leader in the production of DNA, RNA and protein in the genomic medicine space, today announced the planned opening of its new Innovation Center in Waltham, Massachusetts. The milestone marks a bold step in Aldevron's mission to accelerate innovation in genomic medicines while deepening its presence in one of the world's most dynamic biotech hubs. "Establishing a presence in Waltham puts Aldevron at the crossroads of scientific discovery.' - Venkta Indurthi, CSO of Aldevron Share The new Waltham site is designed to fast-track advancements in the manufacture of DNA, RNA and proteins for advanced therapies, expanding Aldevron's capabilities in cell-free DNA, molecular biology, gene editing, and mRNA analytics. By establishing a base in the Boston area, Aldevron is positioning itself at the epicenter of biotech innovation—enabling closer collaboration with clients, faster project timelines and enhanced support for the development of advanced therapies. 'Establishing a presence in Waltham puts Aldevron at the crossroads of scientific discovery,' said Venkata Indurthi, Chief Scientific Officer at Aldevron. 'This Innovation Center is a launchpad for transformative research, empowering us to innovate, collaborate and grow alongside the brightest minds in biotech.' The Waltham Innovation Center will complement Aldevron's established scientific teams in Fargo, ND, and Madison, WI, and will serve as a catalyst for recruiting top talent from Boston's vibrant biotech community. 'Our recent role in the groundbreaking 'Baby KJ' CRISPR therapy delivery demonstrates the life-changing impact that comes from investing in innovation,' said Jennifer Meade, President of Aldevron. 'As one of the most established biotech partners in the U.S., this expansion is a natural evolution—opening new opportunities for growth, deeper client partnerships and greater support for the scientists shaping the future of medicine.' About Aldevron Founded in 1998, Aldevron is a global leader in enabling the development of next-generation genomic medicines. As part of Danaher Corporation, Aldevron empowers scientists and innovators worldwide to advance transformative therapies that are redefining the future of medicine. Aldevron's expertise and integrated solutions have supported landmark achievements—including playing a key role in manufacturing the world's first mRNA-based personalized CRISPR therapy. With facilities in Fargo, ND, Madison, WI and Waltham, MA, Aldevron is at the forefront of accelerating scientific discovery and expanding the possibilities of gene editing, gene therapy and other breakthrough modalities. By partnering with leading researchers and organizations, Aldevron is helping to turn the promise of genomic medicine into reality for patients around the globe. To learn more about how Aldevron is advancing biological science, visit and follow the company on LinkedIn, Facebook and YouTube. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at
Yahoo
13 hours ago
- Business
- Yahoo
Mettler-Toledo (MTD) To Report Earnings Tomorrow: Here Is What To Expect
Precision measurement company Mettler-Toledo (NYSE:MTD) will be reporting results this Thursday after market hours. Here's what you need to know. Mettler-Toledo beat analysts' revenue expectations by 1% last quarter, reporting revenues of $883.7 million, down 4.6% year on year. It was a slower quarter for the company, with a miss of analysts' full-year EPS guidance estimates. Is Mettler-Toledo a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Mettler-Toledo's revenue to be flat year on year at $955.4 million, improving from the 3.6% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $9.60 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Mettler-Toledo has missed Wall Street's revenue estimates three times over the last two years. Looking at Mettler-Toledo's peers in the research tools & consumables segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Thermo Fisher delivered year-on-year revenue growth of 3%, beating analysts' expectations by 1.6%, and Danaher reported revenues up 3.4%, topping estimates by 1.7%. Thermo Fisher traded up 11.3% following the results while Danaher was also up 5.3%. Read our full analysis of Thermo Fisher's results here and Danaher's results here. Investors in the research tools & consumables segment have had fairly steady hands going into earnings, with share prices down 1.8% on average over the last month. Mettler-Toledo is up 7.8% during the same time and is heading into earnings with an average analyst price target of $1,271 (compared to the current share price of $1,266). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
20 hours ago
- Business
- Yahoo
Revvity trims 2025 profit forecast as China policy changes hit diagnostics demand
By Siddhi Mahatole (Reuters) -Revvity on Monday lowered its full-year adjusted profit forecast as it expects demand for diagnostics products in its key market China to be hurt by changes to the country's reimbursement policy, sending the company's shares down nearly 10%. The medical equipment maker said that it now expects sales of its diagnostics products to grow in the low single digits this year, compared to its previous forecast of mid-single digit growth. Sales in China for diagnostic products declined by double digits in the second quarter. "We are now expecting a fairly meaningful pullback in the immunodiagnostics business in China," said CEO Prahlad Singh. China's hospital lab reimbursement policy changes tied to Diagnosis Related Groups (DRGs), have reduced demand for Revvity's higher-value diagnostic products and significantly hurt revenues. Medical device maker Abbott recently said its diagnostics division will be hit hardest, with a projected $700 million revenue impact in 2025 due to fading COVID test sales and pricing pressure from China's procurement program that buys medical devices in bulk at steep discounts. These changes, which took effect in late April, have prompted physicians to reduce their orders for multiplex diagnostic products used to test for multiple conditions simultaneously, Revvity said. Instead, healthcare providers are increasingly opting for single-plex tests - simpler, less comprehensive diagnostics that Revvity also supplies. Last week, larger peer Danaher reported improving conditions in China's pharma and biotech sectors, though it said diagnostics demand in the country remains under pressure. Thermo Fisher Scientific and Danaher both raised their annual profit forecasts. In contrast, Revvity said it expects adjusted profit per share for 2025 between $4.85 and $4.95, down from its previous projection of $4.90 to $5. Despite the hit, Revvity's second-quarter results aligned with industry peers and life sciences product sales reached $365.9 million, surpassing estimates of $353.9 million. The Massachusetts-based company expects full-year revenue of $2.84 billion to $2.88 billion, slightly above its prior forecast of $2.83 billion to $2.87 billion, aided by a weaker U.S. dollar. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
